XLO Xilio Therapeutics, Inc. Stock Quote

XLO [NASD]

Index	-	P/E	-	EPS (ttm)	-107.16	Insider Own	2.70%	Shs Outstand	30.10M	Perf Week	-2.44%
Market Cap	409.96M	Forward P/E	-	EPS next Y	-3.19	Insider Trans	254.40%	Shs Float	23.61M	Perf Month	17.31%
Income	-	PEG	-	EPS next Q	-1.17	Inst Own	55.20%	Short Float	1.70%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-219.00%	Inst Trans	-	Short Ratio	2.54	Perf Half Y	-
Book/sh	-175.18	P/B	-	EPS next Y	41.20%	ROA	-	Target Price	34.75	Perf Year	-
Cash/sh	3.32	P/C	4.11	EPS next 5Y	-	ROE	-	52W Range	8.52 - 27.95	Perf YTD	-14.88%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-51.27%	Beta	-
Dividend %	-	Quick Ratio	8.20	Sales past 5Y	-	Gross Margin	-	52W Low	59.77%	ATR	1.57
Employees	69	Current Ratio	8.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	45.70	Volatility	11.77% 10.64%
Optionable	No	Debt/Eq	-	EPS Q/Q	-41.20%	Profit Margin	-	Rel Volume	0.11	Prev Close	15.37
Shortable	Yes	LT Debt/Eq	-	Earnings	Dec 02 BMO	Payout	-	Avg Volume	157.59K	Price	13.62
Recom	1.70	SMA20	-9.47%	SMA50	-14.73%	SMA200	-17.73%	Volume	17,877	Change	-11.39%

Jan-10-22

Initiated

H.C. Wainwright

Buy

$36

Nov-16-21

Initiated

Raymond James

Outperform

$31

Nov-16-21

Initiated

Morgan Stanley

Overweight

$32

Nov-16-21

Initiated

Guggenheim

Buy

$40

Nov-16-21

Initiated

Cowen

Outperform

Jan-20-22 07:30AM	Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors GlobeNewswire +9.79%
Jan-06-22 07:30AM	Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors GlobeNewswire
Dec-02-21 07:30AM	Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results GlobeNewswire -12.46%
Nov-12-21 07:00AM	Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting GlobeNewswire -6.69%
Oct-27-21 07:45AM	4 Stocks Insiders Are Buying Benzinga
Oct-26-21 04:05PM	Xilio Therapeutics Announces Closing of Initial Public Offering GlobeNewswire

Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bain Capital Life Sciences Inv	10% Owner	Dec 10	Buy	9.65	25,000	241,202	2,805,413	Dec 10 08:33 PM
Bain Capital Life Sciences Inv	10% Owner	Dec 09	Buy	9.84	4,011	39,485	2,780,413	Dec 10 08:33 PM
Bain Capital Life Sciences Inv	10% Owner	Dec 08	Buy	9.62	13,458	129,474	2,776,402	Dec 10 08:33 PM
RiverVest Venture Fund IV, L.P	10% Owner	Oct 26	Buy	16.00	250,000	4,000,000	1,441,444	Oct 26 05:30 PM
Rock Springs Capital Managemen	10% Owner	Oct 26	Buy	16.00	500,000	8,000,000	1,256,472	Oct 26 05:04 PM
BAY CITY CAPITAL LLC	10% Owner	Oct 26	Buy	16.00	312,500	5,000,000	1,129,490	Oct 26 05:02 PM
Atlas Venture Fund XI, L.P.	10% Owner	Oct 26	Buy	16.00	187,500	3,000,000	735,942	Oct 26 05:01 PM
Flynn James E	Possible Member of 10% Group	Oct 26	Buy	16.00	775,000	12,400,000	1,143,972	Oct 28 07:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience